N-acetylcysteine for therapy-resistant tobacco use disorder: A pilot study

Redox Report

Volumn 20, Issue 5, 2015, Pages 215-222

  Prado, Eduardo ^a   Maes, Michael ^a,b,c   Piccoli, Luiz Gustavo ^a   Baracat, Marcela ^a   Barbosa, Décio Sabattini ^a   Franco, Olavo ^a   Dodd, Seetal ^b,d   Berk, Michael ^b,d,e,f   Nunes, Sandra Odebrecht Vargas ^a  

^a STATE UNIVERSITY OF LONDRINA   (Brazil)

^b DEAKIN UNIVERSITY   (Australia)

^c CHULALONGKORN UNIVERSITY   (Thailand)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e UNIVERSITY OF MELBOURNE   (Australia)

^f BARWON HEALTH   (Australia)

Author keywords

Depression; Glutathione; Inflammation; N Acetylcysteine; Oxidative stress; Smoking cessation

Indexed keywords

ACETYLCYSTEINE; CARBON MONOXIDE; EXHALED CARBON MONOXIDE; PLACEBO; UNCLASSIFIED DRUG; GLUTATHIONE;

ADULT; AGED; ARTICLE; BEHAVIOR THERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; EVENING DOSAGE; FEMALE; HAMILTON DEPRESSION RATING SCALE; HUMAN; MALE; MORNING DOSAGE; NAUSEA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT ALLERGY; SKIN ALLERGY; SMOKING; SMOKING CESSATION; TOBACCO DEPENDENCE; WITHDRAWAL SYNDROME; ADOLESCENT; DRUG EFFECTS; METABOLISM; MIDDLE AGED; OXIDATIVE STRESS; PILOT STUDY; TOBACCO USE DISORDER; TREATMENT OUTCOME; YOUNG ADULT;

NICOTIANA TABACUM;

ACETYLCYSTEINE; ADOLESCENT; ADULT; AGED; DOUBLE-BLIND METHOD; FEMALE; GLUTATHIONE; HUMANS; MALE; MIDDLE AGED; OXIDATIVE STRESS; PILOT PROJECTS; TOBACCO USE DISORDER; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84930219432     PISSN: 13510002     EISSN: 17432928     Source Type: Journal    
DOI: 10.1179/1351000215Y.0000000004     Document Type: Article

References (44)

1. Morris G, Anderson G, Dean O, Berk M, Galecki P, Martin-Subero M, Maes M. The glutathione system: a new drug target in neuroimmune disorders. Mol Neurobiol. Epub ahead of print 18 April. 2014. DOI: 10.1007/s12035-014-8705-x.
2. Berk M, Malhi GS, Gray LJ, Dean OM. The promise of N-acetylcysteine in neuropsychiatry. Trends Pharmacol Sci 2013;34:167-77.
3. Dodd S, Dean O, Copolov DL, Malhi GS, Berk M. N-Acetylcysteine for antioxidant therapy: pharmacology and clinical utility. Exp Opin Biol Ther 2008;8:1955-62.
4. Mardikian PN, LaRowe SD, Hedden S, Kalivas PW, Malcolm J. An open-label trial of N-acetylcysteine for the treatment of cocaine dependence: a pilot study. Prog Neuropsychopharmacol Biol Psychiatr 2007;31:389-94.
5. Zhou W, Kalivas PW. N-acetylcysteine reduces extinction responding and induces enduring reductions in cue- and heroin-induced drug-seeking. Biol Psychiatr 2008;63:338-40.
6. Azevedo E, Mendes AC, Berk M, Brietzke E. Systematic review of N-acetylcysteine in the treatment of addictions. Rev Bras Psiquiatr Epub ahead of print 18 may 2014 DOI: 10.1590/ 1516-4446-2013-1244.
7. Bossert JM, Liu SY, Lu L, Shaham A. A role of ventral tegmen-tal area glutamate in contextual cue-induced relapse to heroin seeking. J Neurosci 2004;24:10726-30.
8. Schmaal L, Berk L, Hulstijn KP, Cousijn J, Wiers RW, Van den Brink W. Efficacy of N-acetylcysteine in the treatment of nicotine dependence: a double blind placebo-controlled pilot study. Eur Addict Res 2011;17:211-16.
9. Dean O, Giorland F, Berk M. N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action. J Psychiatr Neurosci 2011;36:78-86.
10. Kalivas P, Volkow N. The neural of addiction: a pathology of motivation and choice. Am J Psychiatr 2005;162:1403-13.
11. Koob G. Neurobiology of addiction. Focus. 2011;9:55-65.
12. Gould NS, Min E, Gauthier S, Martin RJ, Day BJ. Lung gluta- thione adaptive responses to cigarette smoke exposure. Respiratory Res 2011;12:133.
13. Madayag A, Lobner D, Kau KS, Mantsch JR, Abdulhameed O, Hearing M, Grier MD, Baker DA. Repeated N-acetylcysteine administration alters plasticity-dependent effects of cocaine. J Neurosci 2007;27:13968-76.
14. Knackstedt LA, LaRowe S, Mardikian P, Malcom R, Upadhyaya H, Hedden S, Markou A, Kalivas PW. The role of cystine glutamate exchange in nicotine dependence in rats and humans. Biol Psychiatr 2009;65:841-5.
15. Bortolasci CC, Vargas HO, Souza-Nogueira A, Barbosa DS, Moreira EG, Nunes SO, Berk M, Dodd S, Maes M. Lowered plasma paraoxonase (PON)1 activity is a trait marker of major depression and PON1 Q192R gene polymorphism-smoking interactions differentially predict the odds of major depression and bipolar disorder. J Affect Disord 2014;159:23-30.
16. Nunes SOV, De Castro MRP, Watanabe MAW, Guembarovski RL, Vargas HO, Reiche EM, Kaminami HM, Dodd S, Berk M. Genetic polymorphisms in glutathione-S-transferases are associated with anxiety and mood disorders in nicotine dependence. Psychiatr Genet 2014;24:87-93.
17. Antonelli RC. Nicotine-related disorders. In: Gabbard, GO Gabbard's treatment of Psychiatric disorders- DSM-5 Edition. (5th edn) Washington: American Psychiatric Publishing. 2014; pp. 871 -83.
18. Berk M, Copolov DL, Dean O, Lu K, Jeavons S, Schapkaitz I, Anderson-Hunt M, Judd F, Katz F, Katz P, Ording-Jespersen S, Little J, Conus P, Cuenod M, Do KQ, Bush AI. N-acetyl cysteine as a glutathione precursor for schizophrenia-- a double-blind, randomized, placebo-controlled trial. Biol Psychiatr 2008;64: 361-58.
19. Berk M, Dean OM, Cotton SM, Jeavons S, Tanious M, Kohlmann K, Hewitt K, Moss K, Allwang C, Schapkaitz I, Robbins J, Cobb H, Ng F, Dodd S, Bush AI, Malhi GS. The efficacy of adjunctive N-acetylcysteine in major depressive disorder: a double-blind, randomized, placebo-controlled trial. J Clin Psychiatr 2014;75:628-36.
20. Berk M, Ng F, Dean O, Dodd S, Bush AI. Glutathione: a novel treatment target in psychiatry. Trends Pharmacol Sci 2008;29: 346-51.
21. Del Ben CM, Vilela JAA, Crippa JAS, Hallak JEC, Labate CM, Zuardi AW. Reliability of the ‘Structured Clinical Interview for DSM - IV’ - clinical version translated into Portuguese. Rev Bras Psychiatr 2001;23:156-9.
22. Centers for Disease Control and Prevention (CDC). Quitting smoking among adults: United States, 2001-2011. MMWR Morb Mortal Weekly Rep 2011;60:1513-9.
23. Fagerstrom KO, Schneider NG. Measuring nicotine dependence: a review of the Fagerstrom Tolerance Questionnaire. J Behav Med 1989;12:159-82.
24. Carmo JT, Pueyo AA. Adaptation to Portuguese of the Fagerstrom Test for Nicotine Dependence (FTND) to assess dependence and tolerance to nicotine in smokers. Rev Bras Med 2002;59:73-80.
25. Storr CL, Reboussin BA, Anthony JC. The Fagerstrom test for nicotine dependence: a comparison of standard scoring and latent class analysis approaches. Drug Alcohol Depend 2005; 80:241-250.
26. Reichert J, Araujo AJ, Gongalves CMC, Godoy I, Chatkin JM, Sales MPU, Santos SRRA. BTA guidelines: guidelines for smoking cessation - 2008. J Bras Pneumol 2008;34:845-80.
27. Middleton ET, Morice AH. Breath carbon monoxide as an indication of smoking habit. Chest 2000;117:758-63.
28. Moreno RA, Moreno DH. Hamilton and Montgomery & Asberg depression rating scales. Rev Psychiatr Clin 1998;25: 262-72.
29. Sheehan DV, Harnett-Sheehan K, Raj BA. The measurements of disability. Int Clin Psychopharmacol 1996;3(III Suppl.):89-95.
30. Garcia RJ, Francis L, Dawood M, Lai ZW, Faraone SV, Perl A. Attention deficit and hyperactivity disorder scores are elevated and respond to N-acetylcysteine treatment in patients with systemic lupus erythematous. Arthr Rheumat 2013;65: 1313-18.
31. Pasco JA, Williams LJ, Jacka FN, Ng F, Henry MJ, Nicholson GC, Kotowicz MA. Tobacco smoking as a risk factor for major depressive disorder: population-based study. Brit J Psychiatr 2008;193:322-6.
32. Weinberg A, Georg T, Mc Knee S. Differences in smoking expectancies in smokers with and without a history of major depression. Addict Beh 2011;36:434-7.
33. Taylor G, McNeill A, Girling A, Farley A, Lindson-Hawley N, Aveyard P. Change in mental health after smoking cessation: systematic review and meta-analysis. BMJ 2014;13:348, g1151.
34. American Psychiatric Association. Tobacco-related disorders of DSM-5. In: American Psychiatric Association, Diagnostic and statistical manual of mental disorders (5th ed.). Washington, DC: APA; 2013. p. 571-7.
35. Nunes SOV, De Castro MRP, Vargas HO, Vargas MM, Machado RCBR, Fonseca ICB, Dodd S, Berk M. Clinical characteristics and smoking cessation: an analysis of sex and depressive disorders differences. Addict Disord Treatm 2013; 12:158-65.
36. Souza GA, Ebaid GX, Seiva FR, Rocha KH, Galhardi CM, Mani F, Novelli EL. N-acetylcysteine an allium plant compound improves high-sucrose diet-induced obesity and related effects. Evid Based Compl Altern Med 2011;8:1-7.
37. Nunes SO, Vargas HO, Brum J, Prado E, Vargas MM, Castro MR, Berk M. A comparison of inflammatory markers in depressed and nondepressed smokers. Nicotine Tob Res 2012; 14:540-6.
38. Pizzo de Castro MR, Maes M, Guembarovski RL, Ariza CB, Reiche EM, Vargas HO, Vargas MM, de Melo LG, Dodd S, Berk M, Watanabe MA, Nunes SO. SLC6A4 STin2 VNTR genetic polymorphism is associated with tobacco use disorder, but not with successful smoking cessation or smoking characteristics: a case control study. BMC Genet 2014;15:78.
39. Leonard B, Maes M. Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression. Neurosci Biobehav Rev 2012;36:764-85.
40. O’Loughlin J, Lambert M, Karp I, McGrath J, Gray-Donald K, Barnett TA, Delvin EE, Levy E, Paradis G. Association between cigarette smoking and C-reactive protein in a representative, population-based sample of adolescents. Nicotine Tob Res 2008;10:525-32.
41. Hernandez-Lopes S, Garduno J, Mihailescu S. Nicotinic modulation of serotonergic activity in the dorsal raphe nucleus. Rev Neurosci 2013;24:455-69.
42. Khadrawy YA, El-Shamy KAI, Mohamed SI. Nicotine restores monoamine neurotransmitter changes in the cortex and hippocampus of reserpinized rats as a model of depression. Eur Rev Med Pharmacol Sci 2011;15:863-70.
43. Vieyra-Reyes P, Venebra-Munoz A, Rivas-Santiago B, Garria-Garria F. Accion de la nicotina como antidepresivo y regulador del sueno en sujetos deprimidos. Rev Neurol 2009;49:661-7.
44. Chitty KM, Lagopoulos J, Hickie IB, Hermens DF. The impact of alcohol and tobacco use on in vivo glutathione in youth with bipolar disorder: an exploratory study. J Psychiatr Res 2014; 55:59-67.